title: Nilotinib monotherapy induced complete remission in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to imatinib and dasatinib.
authors.affiliation: Department of Pediatrics.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Sekimizu
authors.forename: Yuka
authors.initials: Y
authors.lastname: Yamashita
authors.forename: Hideaki
authors.initials: H
authors.lastname: Ueki
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Akita
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Hattori
authors.forename: Naoko
authors.initials: N
authors.lastname: Maeda
authors.forename: Keizo
authors.initials: K
authors.lastname: Horibe
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002648:Child; D000069439:Dasatinib / Q000494:pharmacology / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D006801:Humans; D000068877:Imatinib Mesylate / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; C498826:nilotinib; D000069439:Dasatinib